Blog

  • Stephen Colbert eyes new gig post ‘Late Show’ exit

    Stephen Colbert eyes new gig post ‘Late Show’ exit

    Stephen Colbert addresses what he plans to do post ‘Late Show’ exit

    Stephen Colbert has recently disclosed what’s next following his Late Show exit. 

    While he might be saying goodbye to The Late Show, the TV personality recently admitted that he is already flirting with his next chapter.

    During the Monday, July 28 episode, the longtime host, welcomed Saturday Night Live favorite Bowen Yang and his Las Culturistas podcast cohost Matt Rogers, per PEOPLE Magazine

    In a refreshingly unfiltered moment, Stepehen Colbert didn’t shy away from addressing the elephant in the room.

    “I’m going to need a gig soon,” he quipped, “so sell me on podcasting. Is it fun?”

    For their part, Bowen Yang and Matt further demonstrated that were all too happy to evangelize. 

    “You start one, we’re getting bumped,” Matt joked of their podcast’s hard-won spot on Time’s list of the 100 best podcasts ever, adding, “Like, almost certainly.”

    “That’s what they wanted, to connect and hear a friendship in action. Hear conversation between people who are over-caffeinated,” he added.

    Advising to keep the content authentic, Matt added, “That’s what resonates.” 


    Continue Reading

  • BTX A51 Demonstrates Tolerability and Manageable Safety Profile in Patients With R/R AML, MDS

    BTX A51 Demonstrates Tolerability and Manageable Safety Profile in Patients With R/R AML, MDS

    Acute myeloid leukemia (AML) cells in blood flow: © LASZLO – stock.adobe.com

    Results from a phase 1 first-in-human dose-escalation study (NCT04872166) evaluating BTX A51 revealed the agent’s tolerability with manageable adverse events, alongside suppressed MCL1 expression in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).1,2

    Brian J. Ball, MD, and colleagues wrote in the study1 that “10% (3 of 31) patients experienced a complete remission with incomplete count recovery (CRi). Specifically, these patients had RUNX1 mutations and the CR/CRi rate for RUNX1-mutated patients receiving BTX A51 at efficacious doses (11 mg or higher) was 30%.” The median duration of response was 1.9 months (range 1.5-2.5), though all 3 responding patients discontinued treatment after relapse.

    Thirty-one patients were enrolled between January 13, 2025 through February 28, 2022, to receive oral doses of BTX A51 ranging from 1 mg to 42 mg 3 days a week. Dosing schedules varied: 1 mg was given 5 days per week for 21 days over a 28-day cycle; 3 mg, 5 mg, 8 mg, 11 mg, 21 mg, and 42 mg doses were administered 3 days per week for 21 days over a 28-day cycle; and a 21 mg dose was also explored 3 days per week for 28 days over a 28-day cycle. Patients remained on treatment for a median of 24 days, with a range of 3 to 135 days.

    The primary end points were safety, maximum tolerated dose, and recommended phase 2 dose based on the incidence of dose-limiting toxicities (DLTs) during cycle 1. Secondary end points included estimated preliminary efficacy, overall and event-free survival, pharmacokinetics, and pharmacodynamics.

    Of the 31 patients, 28 had R/R AML and 3 patients had high-risk R/R MDS. The median age was 75 years (range, 22–84) and the median number of prior lines of therapy was 2 (range, 1-8). Overall, 97% had received prior venetoclax (Venclaxta) and hypomethylating agents and 43% exhibited no response after 2 lines of induction chemotherapy.

    The majority (55%) of patients were male, 3 patients had prior allogeneic hematopoietic cell transplantation, and 12 (38%) harbored RUNX-1–mutated tumors.

    Overall safety showed that all patients had at least 1 treatment-emergent adverse event (TEAE) of any grade with the most common occurring in 10% or more patients were nausea (67%), emesis (63%), hypokalemia (53%), and diarrhea (40%). Reported TEAEs of grade 3 or higher were febrile neutropenia (33%), anemia (33%), thrombocytopenia, and hypokalemia (23% each).

    Investigators determined that 1 patient experienced a DLT during cycle 1 and 1 patient developed a grade 3 elevation in alkaline phosphatase level at the 21 mg dose that resolved 4 days after holding treatment. Another patient experienced encephalopathy and grade 3 hepatic failure with elevations in aspartate aminotransferase, alanine transaminase, and bilirubin, resulting in discontinuation of the 42 mg dose.

    Overall, there were 11 deaths among patients during the study treatment and within 28 days of the last dose. Five of these deaths were attributed to disease progression. Six deaths occurred in the absence of overt disease progression due to lung infection, cardiac arrest, intracranial hemorrhage, fungal infection, and septic shock.

    The investigators also performed in-vitro and ex-vivo studies on AML cell lines and primary patient samples to evaluated antileukemic activity in patients with RUNX1 mutant and wild type. They observed a decrease in the expression of oncogenes such as MYC and MDM2.

    “Importantly, this oncogene suppression, accompanied by the downregulation of the anti-apoptotic protein MCL1, led to the activation of p53 or DNA damage response and subsequent cleavage of caspase 3, thereby inducing leukemia cell apoptosis,” the investigators wrote in their paper.

    These findings were modest but encouraging and the next steps will be exploring the agent in combination with azacitidine and with azacitidine and venetoclax (Venclexta).

    REFERENCES:
    1. Ball B, Xiao W, Borthakur G, et al. Phase I first-in-human dose escalation study of the oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX-A51 in advanced MDS and AML. J Hematol Oncol. 2025 Jul 15;18(1):73. doi: 10.1186/s13045-025-01724-z.
    2. Ball B, Xiao W, Borthakur G, et al. Phase I first-in-human dose escalation study of the oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX-A51 in advanced MDS and AML. Preprint. Res Sq. 2024;rs.3.rs-4954060. Published 2024 Oct 15. doi:10.21203/rs.3.rs-4954060/v1

    Continue Reading

  • Foldable iPhone Will Launch September 2026 for a Cool $1,999, Report Says

    Foldable iPhone Will Launch September 2026 for a Cool $1,999, Report Says

    The trickle of leaks about Apple’s first foldable iPhone continue, and we’re starting to get a clearer picture of what’s in store for the new kind of iPhone reportedly launching next year.

    The first foldable iPhone is expected to be revealed in September 2026 during Apple’s annual iPhone event, according to a report from financial services firm JPMorgan, at a price of $1,999. It will be part of Apple’s iPhone 18 lineup, the report said. The iPhone will reportedly include these features:

    Apple didn’t immediately respond to a request for comment.

    Apple is the only major player in the industry without a foldable phone. Samsung, Google and Motorola have already jumped into the game, with the Galaxy Z Fold 6, Motorola Razr Plus and Pixel 9 Pro Fold raising the stakes with upgraded design features and better screen bending and flexing.

    US consumers are still lukewarm on foldables — a recent CNET survey showed 64% of people we surveyed aren’t willing or interested in buying a foldable phone within the next year, and just 13% are interested. So the iPhone “Flip” could be a game changer in the segment. However, CNET has some words of warning for the Flip to avoid being “a generic, redundant novelty” among competitors.

    In a discussion on r/Apple, some folks said they were excited by the first foldable iPhone but others were more cautious, suggesting they’d wait for a future model. “Everyone I know with a foldable phone has screen issues,” one person wrote.
    Another said, “my biggest concern is longevity / durability.”


    Continue Reading

  • Gedatolisib-Based Regimens Prolong PFS in HR+/HER2–, PIK3CA Wild-Type Advanced Breast Cancer

    Gedatolisib-Based Regimens Prolong PFS in HR+/HER2–, PIK3CA Wild-Type Advanced Breast Cancer

    HR+/HER2– Breast Cancer | Image credit:

    © Sebastian Kaulitzki – stock.adobe.com

    Treatment with gedatolisib, a pan‑PI3K/mTOR inhibitor, in combination with palbociclib (Ibrance) and fulvestrant (Faslodex) or in combination with fulvestrant alone led to clinically meaningful improvements in progression‑free survival (PFS) compared with fulvestrant alone in patients with hormone receptor–positive/HER2‑negative advanced breast cancer who had PIK3CA wild‑type disease, according to topline data from the PIK3CA wild-type cohort of the phase 3 VIKTORIA‑1 trial (NCT05501886).1

    Specifically, the gedatolisib triplet reduced the risk of disease progression or death by 76% compared with fulvestrant alone (HR, 0.24; 95% CI, 0.17-0.35; P < .0001). The median PFS was 9.3 months with the triplet vs 2.0 months with fulvestrant per blinded independent central review (BICR).

    Gedatolisib plus fulvestrant reduced the risk of disease progression or death by 67% compared with fulvestrant alone (HR, 0.33; 95% CI, 0.24-0.48; P < .0001). The median PFS was 7.4 months vs 2.0 months, respectively.

    Full results from the PIK3CA wild‑type cohort will be presented at an upcoming medical congress in 2025. Celcuity plans to submit a new drug application for gedatolisib to the FDA in the fourth quarter of 2025.

    “Patients with hormone receptor-positive, HER2-negative, PIK3CA wild-type advanced breast cancer whose disease has progressed while on, or after, treatment with a CDK4/6 inhibitor typically derive limited benefit from subsequent endocrine-based therapy. The topline data for both gedatolisib regimens from VIKTORIA-1 are potentially practice-changing,” Sara Hurvitz, MD, senior vice president of the Clinical Research Division at Fred Hutchinson Cancer Center; professor and head of the Division of Hematology and Oncology at the University of Washington, Department of Medicine; and co-principal investigator for the trial, stated in a news release.

    VIKTORIA‑1 Trial Breakdown

    VIKTORIA‑1 is a phase 3, open‑label, randomized study evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib in patients with locally advanced or metastatic hormone receptor–positive/HER2‑negative breast cancer who experienced disease progression on or after a CDK4/6 inhibitor and non‑steroidal aromatase inhibitor therapy.2

    Patients needed to have histologically or cytologically confirmed metastatic or locally advanced disease, and they needed to be amendable to treatment with an LHRH agonist. Documented radiological disease progression on or after the last line of therapy was required, and patients needed to have radiologically evaluable disease that was measurable or non-measurable. An ECOG performance status of 0 or 1, a life expectancy of at least 3 months, and adequate bone marrow, hepatic, renal, and coagulation function were required.

    Patients were stratified by confirmed PIK3CA mutation status prior to randomization. Within the PIK3CA wild‑type and PIK3CA‑mutated subgroups, patients were randomly assigned to receive gedatolisib at 180 mg on days 1, 8, and 15 of each 28-day cycle plus palbociclib at 125 mg per day for 3 weeks on and 1 week of in each cycle, and 500 mg of fulvestrant on days 1 and 15 of cycle 1, then on day 1 of subsequent cycles; gedatolisib plus fulvestrant on the same dosing schedules; or fulvestrant alone on the same schedule.

    The primary end point of the trial is PFS, assessed in both PIK3CA wild‑type and PIK3CA‑mutated cohorts. Secondary end points include overall survival (OS), objective response rate, duration of response, clinical benefit rate, safety and tolerability, and patient‑reported outcomes.

    Safety Analysis

    Treatment discontinuations due to treatment‑related adverse effects (TRAEs) were lower for both the triplet and doublet regimens compared with Arm D of the phase 1b trial (NCT02684032) in advanced breast cancer and lower than reported in any phase 3 trials of currently approved combinations in this disease setting.1 The incidence of hyperglycemia and stomatitis was also lower than that observed in the previously reported phase 1b trial.

    “To my knowledge, we have not seen phase 3 results in patients with hormone receptor–positive, HER2-negative advanced breast cancer before where there was a quadrupling of the likelihood of survival without disease progression relative to the study control,” Hurvitz added.

    Reference

    1. Celcuity announces clinically meaningful improvement in both progression-free survival (“PFS”) primary endpoints from PIK3CA wild-type cohort of phase 3 VIKTORIA-1 trial. News Release. Celcuity. July 28, 2025. Accessed July 29, 2025. https://ir.celcuity.com/press-releases/
    2. Gedatolisib plus fulvestrant with or without palbociclib vs standard-of-care for the treatment of patients with advanced or metastatic HR+/HER2- breast cancer (VIKTORIA-1). ClinicalTrials.gov. Updated June 24, 2025. Accessed July 29, 2025. https://clinicaltrials.gov/study/NCT05501886

    Continue Reading

  • CMS proposes new behavioral health integration add-on codes for APCM services in CY 2026 MPFS

    The Centers for Medicare and Medicaid Services (CMS) issued the calendar year (CY) 2026 Medicare Physician Fee Schedule (MPFS) Proposed Rule (Proposed Rule) on July 14, 2025. The Proposed Rule includes important proposals to facilitate the addition of behavioral health integration (BHI) and collaborative care management (CoCM) services by physicians, practitioners, rural health clinics (RHCs), and federally qualified health centers (FQHCs) that provide advanced primary care management (APCM) to Medicare beneficiaries.

    In this alert, we summarize the key proposed changes for healthcare providers and accountable care organizations (ACOs).

    Behavioral health integration add-on codes for advanced primary care management

    CMS proposes the creation of three optional G-codes (GPCM1, GPCM2, and GPCM3) to be billed as add-on services to APCM base codes (G0556, G0557, and G0558) when reported in the same month by the same practitioner. The proposed add-on codes are intended to support the integration and billing of complementary BHI or CoCM services with APCM, with the goal of promoting better patient health and preventing chronic disease.

    The codes would also be considered a “designated care management service” incident to the billing practitioner’s professional services and, as such, could be provided by auxiliary personnel under the general supervision of the billing practitioner.

    Code structure and valuation

    CMS states that the services encompassed by the proposed optional add-on codes should be directly comparable to existing BHI and CoCM codes. CMS cross-walks each proposed optional add-on code to its corresponding BHI or CoCM Current Procedural Terminology (CPT) code values for both practice expense and work relative value units (RVUs). Specifically:

    • GPCM1 mirrors CPT 99492, which is the CPT code for the first month of CoCM services
    • GPCM2 mirrors CPT 99493, which is the CPT code for subsequent months of CoCM services, and
    • GPCM3 mirrors CPT 99484, which is a CPT code for 20 minutes or more of BHI services.

    CMS also proposes allowing RHCs/FQHCs to use the new add-on codes for APCM services. However, to implement this change, CMS states that it would need to modify current RHC/FQHC billing and payment policies for CoCM services.

    Under existing policy, CMS requires RHCs/FQHCs to report CoCM services using a bundled CoCM code (G0512) and sets payment for the bundled services at the annual average of the national non-facility Medicare fee schedule rate for CoCM codes 99492 and 99493.

    Under the CY 2026 proposal, RHCs/FQHCs would no longer use G0512 or be paid the bundled rate. Instead, RHCs/FQHCs would be required to bill using individual CoCM codes, and they would receive the national non-facility Medicare fee schedule payment rates set for such codes.

    Documentation

    CMS proposes removing the time-based documentation requirements for both existing BHI and CoCM codes, and will not impose these requirements for the proposed optional add-on codes. CMS cites the need for providers furnishing APCM services to be able to provide BHI and CoCM without the burden of documenting their time spent performing the service. Specifically, CMS reasons that many practices that develop interdisciplinary teams to provide APCM are the ones most likely ready to furnish BHI and CoCM services, and that introduction of the add-on codes will streamline processes.

    CMS believes that removing the time-based documentation would facilitate a more holistic, team-based approach to care coordination. Further, CMS anticipates that reducing documentation requirements may make primary care practitioners more likely to offer and furnish BHI and CoCM services, thereby improving access for primary care patients.

    Changes to the definition of “primary care services” for ACO beneficiary assignment

    CMS proposes amending the definition of “primary care services” used for assigning beneficiaries to Medicare Shared Savings Program ACOs in two key ways:

    1. Inclusion of new BHI/CoCM codes: The Proposed Rule adds “Enhanced Care Model Management Services” to the definition of “primary care services.” These services are comprised of the optional add-on BHI and CoCM service codes – ie, Healthcare Common Procedure Coding System (HCPCS) codes GPCM1, GPCM2, and GPCM3. CMS believes that including such services in the definition will “increase the accuracy of assignment based on the provision of primary care by ensuring that all expenditures for BHI and CoCM are used to determine beneficiary assignment.”
    2. Deletion of Social Determinants of Health code: CMS proposes to delete HCPCS code G0136 for Social Determinants of Health (SDOH) risk assessment services from the definition of “primary care services,” arguing that existing evaluation and management (E/M) service codes already encompass the costs of the service, rendering payments for SDOH risk assessment services duplicative.

    Next steps for stakeholders

    CMS is actively seeking feedback on numerous proposals within the Proposed Rule. Interested stakeholders – particularly interdisciplinary care teams, primary care providers, and ACOs – are encouraged to submit comments to CMS, which are due by September 12, 2025.

    Key areas for consideration and feedback include:

    • CMS’s proposed valuation and direct cross-walking of the proposed APCM add-on codes to existing BHI and CoCM service codes. Stakeholders should consider evaluating whether the new add-on codes and the removal of time-based documentation requirements will streamline care delivery and billing practices.
    • Proposed changes to the definition of “primary care services” for beneficiary assignment and prospective monthly payments to primary care providers by ACOs for APCM services.
    • Whether CMS should consider: (1) new payments to Medicare Shared Savings Program ACOs for prospective monthly APCM payments to primary care practices that fulfill the APCM billing requirements, with payments reconciled under the ACO benchmark; and (2) additional changes to APCM policies, coding, and/or payments that would generate primary care providers’ interest in ACO participation.

    CMS is also evaluating whether APCM services should be defined to include a blend of preventative and treatment services, given that CMS believes balancing these services is often necessary for effective care management.

    CMS is seeking comments on whether it should include the annual wellness visit, depression screening, or other preventative services in the APCM bundles and, if so, how CMS should apply cost-sharing to APCM services – particularly given that cost-sharing obligations are waived for preventative services under Medicare.

    Learn more

    If you have questions about the Proposed Rule, related advocacy efforts, or need assistance evaluating the regulatory impact of the Proposed Rule and possible implications for your organization – or if you need assistance drafting and preparing comments to the Proposed Rule by September 12, 2025 – please contact your DLA Piper relationship partner, the authors of this alert, or any member of our Healthcare practice group.

    Continue Reading

  • Sun plays peak-a-boo with spacecraft during eclipse | Northwest & National News

    Sun plays peak-a-boo with spacecraft during eclipse | Northwest & National News



























    Sun plays peak-a-boo with spacecraft during eclipse | Northwest & National News | nbcrightnow.com


    We recognize you are attempting to access this website from a country belonging to the European Economic Area (EEA) including the EU which
    enforces the General Data Protection Regulation (GDPR) and therefore access cannot be granted at this time.

    For any issues, contact news@kndu.com or call 509-737-6725.

    Continue Reading

  • WHO urges urgent action to eliminate hepatitis and reduce liver cancer deaths

    WHO urges urgent action to eliminate hepatitis and reduce liver cancer deaths

    As we mark World Hepatitis Day, WHO calls on governments and partners to urgently accelerate efforts to eliminate viral hepatitis as a public health threat and reduce liver cancer deaths.

    Every 30 seconds, someone dies from a hepatitis-related severe liver disease or liver cancer. Yet we have the tools to stop hepatitis.”


    Dr. Tedros Adhanom Ghebreyesus, WHO Director-General

    Viral hepatitis – types A, B, C, D, and E – are major causes of acute liver infection. Among these only hepatitis B, C, and D can lead to chronic infections that significantly increase the risk of cirrhosis, liver failure, or liver cancer. Yet most people with hepatitis don’t know they’re infected. Types B, C, and D affect over 300 million people globally and cause more than 1.3 million deaths each year, mainly from liver cirrhosis and cancer.

    Hepatitis D now classified as carcinogenic

    The International Agency for Research on Cancer (IARC) recently classified hepatitis D as carcinogenic to humans, just like hepatitis B and C. Hepatitis D, which only affects individuals infected with the hepatitis B, is associated with a two- to six-fold higher risk of liver cancer compared to hepatitis B alone. This reclassification marks a critical step in global efforts to raise awareness, improve screening, and expand access to new treatments for hepatitis D.

    “WHO has published guidelines on testing and diagnosis of Hepatitis B and D in 2024, and is actively following the clinical outcomes from innovative treatments for hepatitis D,” said Dr Meg Doherty, incoming Director of Science for Health at WHO.

    Treatment with oral medicine can cure hepatitis C within 2 to 3 months and effectively suppress hepatitis B with life-long therapy. Treatment options for hepatitis D are evolving. However, the full benefit of reducing liver cirrhosis and cancer deaths can only be realized through urgent action to scale up and integrate hepatitis services – including vaccination, testing, harm reduction, and treatment – into national health systems.

    Latest data and progress

    Encouragingly, the majority of low- and middle-income countries (LMICs) have strategic plans on hepatitis in place and progress in national hepatitis responses is increasing:

    • in 2025, the number of countries reporting national hepatitis action plans increased from 59 to 123;
    • as of 2025, 129 countries have adopted policies for hepatitis B testing among pregnant women, up from 106 reported in 2024; and
    • 147 countries have introduced the hepatitis B birth dose vaccination, an increase from 138 in 2022.

    However, critical gaps remain in service coverage and outcomes, as stated in the 2024 Global Hepatitis Report:

    • testing and treatment coverage remain critically low; only 13% of people with hepatitis B and 36% with hepatitis C had been diagnosed by 2022;
    • treatment rates were even lower – 3% for hepatitis B and 20% for hepatitis C – well below the 2025 targets of 60% diagnosed and 50% treated; and
    • integration of hepatitis services remains uneven: 80 countries have incorporated hepatitis services into primary health care; 128 into HIV programmes and just 27 have integrated hepatitis C services into harm reduction centres.

      The next challenge will be to scale up the implementation of prevention, testing and treatment coverage. Achieving WHO’s 2030 targets could save 2.8 million lives and prevent 9.8 million new infections. With declining donor support, countries must prioritize domestic investment, integrated services, better data, affordable medicines, and ending stigma.

    Forging new partnerships

    To mark World Hepatitis Day, WHO is partnering with Rotary International and the World Hepatitis Alliance to strengthen global and local advocacy. This year’s campaign Hepatitis: Let’s break it down demands action to confront the rising toll of liver cancer linked to chronic hepatitis infections. It also calls for decisive steps to dismantle persistent barriers – from stigma to funding gaps – that continue to slow progress in prevention, testing, and treatment.

    Through a joint webinar and coordinated outreach, the partnership underscores the vital role of civil society and community leadership, alongside governments, in sustaining momentum and accelerating progress toward hepatitis elimination.

    Source:

    The World Health Organization

    Continue Reading

  • Lottie Woad Makes a Big Impression and Already is the Talk of Women's Golf – LPGA

    Lottie Woad Makes a Big Impression and Already is the Talk of Women's Golf – LPGA

    1. Lottie Woad Makes a Big Impression and Already is the Talk of Women’s Golf  LPGA
    2. LPGA’s Kessler, Golf Channel hailed for quick pivot around Lottie Woad’s historic weekend  Sports Business Journal
    3. ‘I know what I need to do’ – rising star Woad targets Open  BBC
    4. Here’s the prize money breakdown for each golfer at the 2025 ISPS HANDA Women’s Scottish Open  Golf Digest Middle East
    5. Golf: Lottie Woad Makes Waves in Her First LPGA Tournament, Surpassing Nelly Korda  Al Bat

    Continue Reading

  • Hadjar endures ‘frustrating’ 2025 Belgian Grand Prix with car issue as Lawson picks up points for Racing Bulls

    Hadjar endures ‘frustrating’ 2025 Belgian Grand Prix with car issue as Lawson picks up points for Racing Bulls

    Isack Hadjar was left to endure a “frustrating” Grand Prix at Spa as he dropped to the back of the field with a car issue, while team mate Liam Lawson delivered points with a strong drive to eighth place.

    The Frenchman had looked okay in the initial stages, running in front of his team mate in P8, but as the track dried the team opted to call Lawson in first – when normally the lead car gets the preferential pit stop.

    Pitting a lap later seemed to cost Hadjar, who dropped way down the order, but it soon became apparent that all was not right for the rookie, who was forced into a second stop despite his medium tyres not being that old.

    That sent him to the back of the pack, where he stayed for the rest of a difficult Grand Prix at Spa-Francorchamps.

    “Unfortunately, we had an issue with the car for almost the whole race and that made me lose quite a lot of lap time,” he explained, without going into any details over what exactly the problem was.

    “We’ll review the reasons why, but I was aware of it whilst I was driving, so I just tried to make the most out of it, doing my best. It was very frustrating, as I felt like the car underneath me was working really well.

    “It’s a shame for the team, as everyone has done an amazing job, and I think it could have been a double-points finish today after Liam’s result. I’m confident going to Budapest, so we’ll bounce back next week.”

    For Lawson, his preferential pit stop brought him out in seventh – but he lost one place to a charging Lewis Hamilton. From there, he had the pace on the mediums to comfortably keep Gabriel Bortoleto at bay, for his second points score in the last three races.

    And it was just reward after the frustrations in the wet at Silverstone, where Lawson crashed out at the start of the race.

    “I really enjoyed today. Often in those conditions you just want to survive, so I’m very happy for the team and how everything came together,” the Kiwi racer said.

    “It’s always tricky when you cross over to a dry tyre when it’s damp, but the car was fast and in clean air we had great pace. A lot of work goes into little details each weekend when the Championship is this tight, so now we need to keep the momentum rolling forward and make sure we enter the summer break on a high.”

    Racing Bulls sit seventh in the Teams’ Championship, and are just two points behind Kick Sauber. Lawson’s points combined with Aston Martin failing to score mean they now have a bit more of a buffer to their rivals, to the tune of five points.

    Continue Reading

  • New Research Suggests Life Could Survive Beneath The Surface Of Mars And Other Planets Using High Energy Particles From Space – astrobiology.com

    1. New Research Suggests Life Could Survive Beneath The Surface Of Mars And Other Planets Using High Energy Particles From Space  astrobiology.com
    2. Earth’s Underground Life Could Exist on Mars, Scientists Say  SciTechDaily
    3. Life could survive beneath the surface of Mars and other planets using high energy particles from space  Phys.org
    4. Scientists Drop Bombshell: “Life Could Thrive Under Mars’ Surface” Sparks Fierce Debate as Experts Warn of Potential Colonization Crisis on Other Worlds  fdupillar.com
    5. Cracked rocks power life deep on Earth – and possibly other planets  Earth.com

    Continue Reading